Home Newsfeeds CICC Initiates Coverage On Livent with Outperform Rating, Announces Price Target of $27.3

CICC Initiates Coverage On Livent with Outperform Rating, Announces Price Target of $27.3

CICC initiates coverage on Livent (NYSE:LTHM) with a Outperform rating and announces Price Target of $27.3.

byBenzinga Newsdesk

August 8, 2022

1 minute read

CICC initiates coverage on Livent (NYSE:LTHM) with a Outperform rating and announces Price Target of $27.3.

Analyst Ratings

What 20 Analyst Ratings Have To Say About Charles Schwab

By Benzinga Insights

June 5, 1:01 PM

Over the past 3 months, 20 analysts have published their opinion on Charles Schwab (NYSE:SCHW) stock. These analysts…

SCHW

Black Stone Minerals Q4 EPS $0.82 Beats $0.41 Estimate, Sales $230.38M Beat $146.07M Estimate

By Benzinga Newsdesk

February 21, 6:41 PM

Black Stone Minerals (NYSE:BSM) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.41 by 100 percent. This is a 36.67 percent increase over earnings of $0.60 per share from the

BSM

Charlotte’s Web Formed Joint Venture With BAT And AJNA Biosciences To Seek FDA Approval For Proprietary Full Spectrum Hemp Extract Botanical Drug; Bat Acquired 20% Stake For $10M, With Charlotte’s Web And Ajna Each Owning 40% In JV

By Charles Gross

April 6, 10:52 AM

BAT acquires 20% stake for US$10 million, with Charlotte's Web and AJNA each owning 40% Renowned neurologist Dr. Orrin Devinsky, Chief Medical Advisor for AJNA, to lead the project

BTI